Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InMed PharmaceuticalsINM -0.73%28 3-1 Month Momentum % is -3.36% as of Sep. 21, 2026. GuruFocus rates INM with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,018 Drug Manufacturers companies, InMed Pharmaceuticals ranks worse than 66.01% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-21), InMed Pharmaceuticals's 3-1 Month Momentum % is -3.36%.
The industry rank for InMed Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
INM's 3-1 Month Momentum % is ranked worse than 66.01% of 1018
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs INM: -3.36
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
InMed Pharmaceuticals 3-1 Month Momentum % Related Terms
INM vs SNOA, GELS, APUS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMed Pharmaceuticals 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals (INM) has a 3-1 Month Momentum % of -3.36% as of Sep. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on InMed Pharmaceuticals and its competitors. According to the industry distribution chart, InMed Pharmaceuticals ranks #672 out of 1018 companies in the Drug Manufacturers industry, placing it in the top 66%.
Is InMed Pharmaceuticals' 3-1 Month Momentum % too high?
InMed Pharmaceuticals' current 3-1 Month Momentum % is -3.36%. Based on the distribution chart, InMed Pharmaceuticals ranks #672 out of 1018 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, InMed Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' 3-1 Month Momentum % compare to SNOA and GELS?
According to the Drug Manufacturers industry distribution chart, InMed Pharmaceuticals ranks #672 out of 1018 companies for 3-1 Month Momentum %. This places InMed Pharmaceuticals in the lower half of its industry. The industry median 3-1 Month Momentum % is 2.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 2.33, based on 1,018 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on InMed Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InMed Pharmaceuticals's current 3-1 Month Momentum % is -3.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
InMed Pharmaceuticals (INM) has a current 3-1 Month Momentum % of -3.36%. The current 3-1 Month Momentum % is -3.36%. InMed Pharmaceuticals' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current 3-1 Month Momentum % is -3.36% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
28GF Score
Get the complete analysis for INM
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INM has been successfully added to your 
